PH12012501153A1 - Process for synthesis of intermediates useful for making substituted indazole and azaindazole compounds - Google Patents

Process for synthesis of intermediates useful for making substituted indazole and azaindazole compounds

Info

Publication number
PH12012501153A1
PH12012501153A1 PH1/2012/501153A PH12012501153A PH12012501153A1 PH 12012501153 A1 PH12012501153 A1 PH 12012501153A1 PH 12012501153 A PH12012501153 A PH 12012501153A PH 12012501153 A1 PH12012501153 A1 PH 12012501153A1
Authority
PH
Philippines
Prior art keywords
synthesis
intermediates useful
substituted indazole
compounds
making substituted
Prior art date
Application number
PH1/2012/501153A
Other languages
English (en)
Inventor
Hossein Razavi
Jonathan Timothy Reeves
Sonia Rodriguez
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PH12012501153A1 publication Critical patent/PH12012501153A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/70Sulfur atoms
    • C07D213/71Sulfur atoms to which a second hetero atom is attached
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J23/00Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
    • B01J23/38Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals
    • B01J23/40Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals of the platinum group metals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
PH1/2012/501153A 2009-12-08 2010-12-01 Process for synthesis of intermediates useful for making substituted indazole and azaindazole compounds PH12012501153A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26753809P 2009-12-08 2009-12-08
PCT/US2010/058594 WO2011071730A1 (en) 2009-12-08 2010-12-01 Process for synthesis of intermediates useful for making substituted indazole and azaindazole compounds

Publications (1)

Publication Number Publication Date
PH12012501153A1 true PH12012501153A1 (en) 2012-10-22

Family

ID=43416915

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2012/501153A PH12012501153A1 (en) 2009-12-08 2010-12-01 Process for synthesis of intermediates useful for making substituted indazole and azaindazole compounds

Country Status (17)

Country Link
US (1) US20110137042A1 (enExample)
EP (1) EP2509952A1 (enExample)
JP (1) JP2013512954A (enExample)
KR (1) KR20120101667A (enExample)
CN (1) CN102596908A (enExample)
AR (1) AR079324A1 (enExample)
AU (1) AU2010328480A1 (enExample)
BR (1) BR112012013582A2 (enExample)
CA (1) CA2782384A1 (enExample)
CL (1) CL2012001300A1 (enExample)
EA (1) EA201200820A1 (enExample)
IL (1) IL219274A0 (enExample)
IN (1) IN2012DN05081A (enExample)
MX (1) MX2012006524A (enExample)
PH (1) PH12012501153A1 (enExample)
TW (1) TW201144282A (enExample)
WO (1) WO2011071730A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5216912B2 (ja) 2008-04-29 2013-06-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ccr1受容体拮抗薬としてのインダゾール化合物
WO2009137338A1 (en) 2008-05-06 2009-11-12 Boehringer Ingelheim International Gmbh Pyrazole compounds as ccr1 antagonists
KR20110060904A (ko) 2008-09-26 2011-06-08 베링거 인겔하임 인터내셔날 게엠베하 Ccr1 수용체 길항제로서의 아자인다졸 화합물
AU2010308277A1 (en) 2009-10-21 2012-04-26 Boehringer Ingelheim International Gmbh Indazole and pyrazolopyridine compounds as CCR1 receptor antagonists
JP5542214B2 (ja) 2009-10-27 2014-07-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ccr1受容体アンタゴニストとしての複素環化合物
WO2011137109A1 (en) 2010-04-30 2011-11-03 Boehringer Ingelheim International Gmbh Azaindazole amide compounds as ccr1 receptor antagonists
JP5684406B2 (ja) 2010-12-23 2015-03-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ccr1受容体アンタゴニストとしてのピラゾロピペリジン化合物

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242931A (en) * 1988-06-09 1993-09-07 Kyowa Hakko Kogyo Co., Ltd. Tricyclic compounds as TXA2 antagonists
CA1338625C (en) * 1988-06-09 1996-10-01 Kyowa Hakko Kogyo Co., Ltd. Tricyclic compounds
US5750542A (en) * 1993-09-28 1998-05-12 Pfizer Benzisoxazole and benzisothizole derivatives as cholinesterase inhibitors
US5612360A (en) * 1992-06-03 1997-03-18 Eli Lilly And Company Angiotensin II antagonists
US5616537A (en) * 1992-07-03 1997-04-01 Kumiai Chemical Industry Co., Ltd. Condensed heterocyclic derivatives and herbicides
GB9304919D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
KR950702555A (ko) * 1993-06-25 1995-07-29 모치츠키 노부히코 인다졸술포닐요소 유도체, 그의 용도 및 제조 중간체(indazolesulfonylurea derivative, its use and intermediate for its production)
AU699281B2 (en) * 1994-12-06 1998-11-26 Merck Sharp & Dohme Limited Azetidine, pyrrolidine and piperidine derivatives as 5HT1 receptor agonists
GB9519563D0 (en) * 1995-09-26 1995-11-29 Merck Sharp & Dohme Therapeutic agents
GB9523583D0 (en) * 1995-11-17 1996-01-17 Merck Sharp & Dohme Therapeutic agents
US5760028A (en) * 1995-12-22 1998-06-02 The Dupont Merck Pharmaceutical Company Integrin receptor antagonists
GB9615449D0 (en) * 1996-07-23 1996-09-04 Merck Sharp & Dohme Therapeutic agents
TR200001256T2 (tr) * 1997-11-04 2000-11-21 Pfizer Products Inc. Terapötik olarak aktif bileşimler.
US6331640B1 (en) * 1998-10-13 2001-12-18 Hoffmann-La Roche Inc. Diaminopropionic acid derivatives
EP1192132B1 (en) * 1999-06-14 2005-09-07 Eli Lilly And Company Serine protease inhibitors
WO2001000656A2 (en) * 1999-06-29 2001-01-04 Ortho-Mcneil Pharmaceutical, Inc. Novel indazole peptidomimetics as thrombin receptor antagonists
GB0030306D0 (en) * 2000-12-13 2001-01-24 Lilly Co Eli Compounds
GB0030304D0 (en) * 2000-12-13 2001-01-24 Lilly Co Eli Compounds
GB0030303D0 (en) * 2000-12-13 2001-01-24 Lilly Co Eli Compounds
GB0030305D0 (en) * 2000-12-13 2001-01-24 Lilly Co Eli Compounds
US20050009876A1 (en) * 2000-07-31 2005-01-13 Bhagwat Shripad S. Indazole compounds, compositions thereof and methods of treatment therewith
US7211594B2 (en) * 2000-07-31 2007-05-01 Signal Pharmaceuticals, Llc Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith
US7058826B2 (en) * 2000-09-27 2006-06-06 Amphus, Inc. System, architecture, and method for logical server and other network devices in a dynamically configurable multi-server network environment
US20020052373A1 (en) * 2000-10-26 2002-05-02 Zorn Stevin H. Combination treatment for dementia or cognitive deficits associated with alzheimer's disease and parkinson's disease
US6995162B2 (en) * 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
WO2003037274A2 (en) * 2001-11-01 2003-05-08 Icagen, Inc. Pyrazole-amides and-sulfonamides
AU2003241925A1 (en) * 2002-05-31 2003-12-19 Eisai R&D Management Co., Ltd. Pyrazole compound and medicinal composition containing the same
TW200500341A (en) * 2002-11-12 2005-01-01 Astrazeneca Ab Novel compounds
SE0203825D0 (sv) * 2002-12-20 2002-12-20 Astrazeneca Ab Novel fused heterocycles and uses thereof
BRPI0408223A (pt) * 2003-03-12 2006-03-01 Celgene Corp composto, isÈmeros, composição farmacêutica, e, métodos de inibir pde4 e mmp, de modular a produção de tnf-alfa em um mamìfero e de tratar, previnir ou controlar uma doença ou condição
US7129264B2 (en) * 2003-04-16 2006-10-31 Bristol-Myers Squibb Company Biarylmethyl indolines and indoles as antithromboembolic agents
US20040220170A1 (en) * 2003-05-01 2004-11-04 Atkinson Robert N. Pyrazole-amides and sulfonamides as sodium channel modulators
EP1664052B1 (en) * 2003-08-15 2009-02-18 AstraZeneca AB Fused heterocycles as inhibitors of glutamate racemase (muri)
SE0302487D0 (sv) * 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
SE0302486D0 (sv) * 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
GB0504828D0 (en) * 2005-03-09 2005-04-13 Merck Sharp & Dohme Therapeutic agents
CA2599555A1 (en) * 2005-03-16 2006-09-21 Basf Aktiengesellschaft Biphenyl-n-(4-pyridyl) methylsufonamides
CN101175488B (zh) * 2005-05-17 2012-04-18 萨可德公司 治疗眼病的组合物和方法
EP1924561B1 (en) * 2005-09-01 2012-11-14 Eli Lilly & Company 6-arylalkylamino- 2,3,4,5-tetrahydro-1h-benzo[d]azepines as 5-ht2c receptor agonists
US20080262040A1 (en) * 2005-10-25 2008-10-23 Smithkline Beecham Corporation Chemical Compounds
CA2644963A1 (en) * 2006-03-31 2007-10-11 Novartis Ag Organic compounds
PE20081775A1 (es) * 2006-12-20 2008-12-18 Bristol Myers Squibb Co Compuestos macrociclicos como inhibidores del factor viia
GB0716292D0 (en) * 2007-08-21 2007-09-26 Biofocus Dpi Ltd Imidazopyrazine compounds
KR20100084516A (ko) * 2007-10-31 2010-07-26 닛산 가가쿠 고교 가부시키 가이샤 피리다지논 유도체 및 이의 p2x7 수용체 억제제로서의 용도
JP5216912B2 (ja) * 2008-04-29 2013-06-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ccr1受容体拮抗薬としてのインダゾール化合物
WO2009137338A1 (en) * 2008-05-06 2009-11-12 Boehringer Ingelheim International Gmbh Pyrazole compounds as ccr1 antagonists
KR20110060904A (ko) * 2008-09-26 2011-06-08 베링거 인겔하임 인터내셔날 게엠베하 Ccr1 수용체 길항제로서의 아자인다졸 화합물

Also Published As

Publication number Publication date
CL2012001300A1 (es) 2012-09-07
BR112012013582A2 (pt) 2016-07-05
CA2782384A1 (en) 2011-06-16
AU2010328480A1 (en) 2012-05-17
CN102596908A (zh) 2012-07-18
MX2012006524A (es) 2012-07-17
EP2509952A1 (en) 2012-10-17
KR20120101667A (ko) 2012-09-14
WO2011071730A1 (en) 2011-06-16
JP2013512954A (ja) 2013-04-18
AR079324A1 (es) 2012-01-18
TW201144282A (en) 2011-12-16
EA201200820A1 (ru) 2013-01-30
IN2012DN05081A (enExample) 2015-10-09
IL219274A0 (en) 2012-06-28
US20110137042A1 (en) 2011-06-09

Similar Documents

Publication Publication Date Title
PT2470546E (pt) Compostos de hexa-hidrooxazinopteridina para serem utilizados como inibidores de mtor
MX2011009369A (es) 2-mercaptoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
IN2012DN02751A (enExample)
TN2011000673A1 (en) Bace inhibitors
TW201129555A (en) Process for the manufacture of dabigatrane etexilate
MX2012003343A (es) Proceso para preparar compuestos azabiciclicos.
MX2011008864A (es) Tetrahidroazolopirazinas sulfoniladas y su uso como productos medicinales.
NI200900151A (es) Nuevo procedimiento de síntesis de la agomelatina.
MY161132A (en) Novel herbicides
MX2011007998A (es) Nuevos herbicidas.
MX2011011776A (es) Nuevos profarmacos de triptolite.
UA102289C2 (ru) Гербициды, полученные из циклопентадиона
MX2011007932A (es) Herbicidas nuevos.
MX2011008825A (es) 3-aminoisoxazolopiridinas sustituidas como moduladores de kcnq2/3.
MY160625A (en) Process for preparing pan-cdk inhibitors of the formula(i), and intermediates in the preparation
NI200900153A (es) Nuevo procedimiento de síntesis de la agomelatina.
UA101835C2 (uk) Спосіб отримання похідних 1-(2-галогенбіфеніл-4-іл)-циклопропанкарбонової кислоти
PH12012501153A1 (en) Process for synthesis of intermediates useful for making substituted indazole and azaindazole compounds
TN2011000355A1 (en) Novel microbiocides
MX2010004546A (es) Nuevos intermedios de pregabalina y procedimiento para prepararlos y para preparar pregabalina.
MX2011008662A (es) 2-mercapto-3-aminopiridinas sustituidas como moduladores de kcnq2/3.
MX2011009338A (es) 3-amino-2-mercaptoquinolinas sustituidas como moduladores de kcnq2/3.
MX2009010903A (es) Metodos para preparar compuestos basados en imidazol.
UA106988C2 (uk) Спосіб одержання 1-бензил-3-гідроксиметил-1h-індазолу і його похідних та необхідні проміжні сполуки магнію
NI200900152A (es) Nuevo procedimiento de síntesis de la agomelatina